{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:05Z","timestamp":1787614805604,"version":"build-2736575974"},"reference-count":142,"publisher":"Medknow","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0019-5154.113930","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T11:39:52Z","timestamp":1372160392000},"page":"255","source":"Crossref","is-referenced-by-count":32,"title":["Systemic sclerosis: Current concepts in pathogenesis and therapeutic aspects of dermatological manifestations"],"prefix":"10.4103","volume":"58","author":[{"given":"Vishalakshi","family":"Viswanath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MeghanaM","family":"Phiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VinayV","family":"Gopalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","reference":[{"key":"key-10.4103\/0019-5154.113930-1","first-page":"203","volume-title":"Genetic background of systemic sclerosis: Autoimmune genes take centre stage","author":"Allanore","year":"2010","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-2","first-page":"2109","volume-title":"Heritability of vasculopathy, autoimmune disease, and fibrosis: A population-based study of systemic sclerosis","author":"Frech","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-3","first-page":"e2696","volume-title":"Molecular subsets in the gene expression signatures of scleroderma skin","author":"Milano","year":"2008","journal-title":"PLos One"},{"key":"key-10.4103\/0019-5154.113930-4","first-page":"13","volume-title":"Scleroderma-New aspects in pathogenesis and treatment, best practice and research","author":"Balbir-Gurman","year":"2012","journal-title":"Clin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-5","doi-asserted-by":"crossref","unstructured":"Goodfield MJ, Jones SK, Veale DJ. The \u2032Connective Tissue Diseases\u2032 In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook\u2032s Textbook of Dermatology. 8 th ed. UK: Wiley Blackwell; 2010. p. 51.87-109.","DOI":"10.1002\/9781444317633.ch51"},{"key":"key-10.4103\/0019-5154.113930-6","first-page":"133","volume-title":"The genetics of scleroderma (systemic sclerosis)","author":"Agarwal","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-7","first-page":"2071","volume-title":"The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype","author":"Rueda","year":"2009","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/0019-5154.113930-8","first-page":"36","volume-title":"Systemic sclerosis and infections","author":"Randone","year":"2008","journal-title":"Autoimmun Rev"},{"key":"key-10.4103\/0019-5154.113930-9","first-page":"244","volume-title":"Do infections facilitate emergence of systemic sclerosis","author":"Grossman","year":"2011","journal-title":"Autoimmune Rev"},{"key":"key-10.4103\/0019-5154.113930-10","doi-asserted-by":"crossref","unstructured":"Varga J, Denton CP. Systemic sclerosis and the scleroderma-spectrum disorders. In: Gray SF, Ralph CB, Edward DH, Iain BM, Shaun R, John SS, editors. Kelly\u2032s Textbook of Rheumatology. 8 th ed. Philadelphia: Saunders Elsevier; 2009. p. 1311-51.","DOI":"10.1016\/B978-1-4160-3285-4.10077-4"},{"key":"key-10.4103\/0019-5154.113930-11","first-page":"490","volume-title":"Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective cohort study and review of the literature","author":"Arnson","year":"2011","journal-title":"Autoimmun Rev"},{"key":"key-10.4103\/0019-5154.113930-12","first-page":"2201","volume-title":"Vitamin D, Parathyroid Hormone, and Acroosteolysis in Systemic Sclerosis","author":"Braun-Moscovici","year":"2008","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-13","first-page":"2492","volume-title":"Significantly decreased serum 25-hydroxyvitamin d levels in a large german systemic sclerosis cohort","author":"Gambichler","year":"2011","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-14","first-page":"1024","volume-title":"Vitamin D levels and potential impact in systemic sclerosis","author":"Vacca","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-15","first-page":"2844","volume-title":"Hypovitaminosis D in Systemic Sclerosis","author":"Calzolari","year":"2009","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-16","first-page":"1419","volume-title":"Very low levels of vitamin D in systemic sclerosis patients","author":"Caramaschi","year":"2010","journal-title":"Clin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-17","first-page":"1924","volume-title":"Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis","author":"Vacca","year":"2009","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-18","first-page":"831","volume-title":"Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease","author":"Abraham","year":"1997","journal-title":"Am J Pathol"},{"key":"key-10.4103\/0019-5154.113930-19","first-page":"297","volume-title":"Progressive loss of lymphatic vessels in skin of patients with systemic sclerosis","author":"Manetti","year":"2011","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-20","first-page":"2191","volume-title":"Epithelial cells promote fibroblast activation via IL-1 alpha in systemic sclerosis.Journal of Investigative Dermatology","author":"Aden","year":"2010","journal-title":""},{"key":"key-10.4103\/0019-5154.113930-21","first-page":"296","volume-title":"Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts","author":"Kadono","year":"1998","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-22","first-page":"3908","volume-title":"Deficient Smad7 expression: A putative molecular defect in scleroderma","author":"Dong","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"key-10.4103\/0019-5154.113930-23","first-page":"713","volume-title":"Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis","author":"Del","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-24","unstructured":"Connolly MK. Systemic sclerosis (scleroderma) and related disorders. In: Callen JF, Horn TH, Mancini AJ, Salasche SJ, Schaffer JV, Schwarz T, et al., editors. Dermatology. 2 nd ed. USA: Mosby Elsevier; 2008. p. 585-96."},{"key":"key-10.4103\/0019-5154.113930-25","first-page":"1751","volume-title":"Type 2 Helper T-Cell Predominance and High CD30 Expression in Systemic Sclerosis","author":"Mavalia","year":"1997","journal-title":"Am J Pathol"},{"key":"key-10.4103\/0019-5154.113930-26","first-page":"695","volume-title":"Immunopathogenesis of systemic sclerosis","author":"White","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"key-10.4103\/0019-5154.113930-27","first-page":"617","volume-title":"Innate immunity and inflammation in systemic sclerosis","author":"Lafyatis","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-28","first-page":"68","volume-title":"Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis","author":"Gupta","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"key-10.4103\/0019-5154.113930-29","first-page":"R22","volume-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key-10.4103\/0019-5154.113930-30","first-page":"733","volume-title":"Immunoreactive beta-melanocyte stimulating hormone and melanin pigmentation in systemic sclerosis","author":"Smith","year":"1976","journal-title":"Br Med J"},{"key":"key-10.4103\/0019-5154.113930-31","first-page":"899","volume-title":"Correlation between diffuse pigmentation and keratinocyte derived endothelin-1 in systemic sclerosis","author":"Tabata","year":"2000","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-32","first-page":"1349","volume-title":"Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis","author":"Davies","year":"2006","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-33","unstructured":"Kanwar AJ, De D. Systemic collagen disorders. In: Valia RG, Valia AR, editors. IADVL textbook of Dermatology. 3 rd ed. Mumbai: Bhalani Publishing House; 2008. p. 1220-66."},{"key":"key-10.4103\/0019-5154.113930-34","first-page":"416","volume-title":"Profile of systemic sclerosis in a tertiary care center in North India","author":"Sharma","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0019-5154.113930-35","first-page":"254","volume-title":"Progressive systemic sclerosis in south India","author":"Krishnamurthy","year":"1991","journal-title":"J Assoc Physics India"},{"key":"key-10.4103\/0019-5154.113930-36","first-page":"332","volume-title":"Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants","author":"Reveille","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-37","first-page":"1112","volume-title":"Health-related quality of life in systemic sclerosis: A systematic review","author":"Hudson","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-38","first-page":"1326","volume-title":"Expert agreement on EULAR\/EUSTAR recommendations for management of systemic sclerosis","author":"Walker","year":"2011","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-39","first-page":"154","volume-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","author":"Johnston","year":"2005","journal-title":"Clin Immunol"},{"key":"key-10.4103\/0019-5154.113930-40","first-page":"1351","volume-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-41","first-page":"218","volume-title":"Evaluation of oral methotrexate in the treatment of systemic sclerosis","author":"Krishna","year":"2007","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-42","first-page":"442","volume-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis- a retrospective analysis","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-43","first-page":"1241","volume-title":"A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset","author":"Mendoza","year":"2012","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-44","first-page":"1104","volume-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","author":"Le","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-45","first-page":"1595","volume-title":"A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis","author":"Derk","year":"2009","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-46","first-page":"35","volume-title":"Low-dose intravenous cyclophosphamide in systemic sclerosis: An open prospective efficacy study in patients with early diffuse disease","author":"Valentini","year":"2006","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-47","first-page":"205","volume-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-48","first-page":"613","volume-title":"Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy","author":"Paone","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-49","first-page":"865","volume-title":"Cyclosporine and Tacrolimus: Their use in routine clinical setting for scleroderma","author":"Morton","year":"2000","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-50","first-page":"75","volume-title":"Cyclosporine in systemic sclerosis.Results of a forty-eight-week open safety study in ten patients","author":"Clements","year":"1993","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-51","first-page":"992","volume-title":"Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy","author":"Filaci","year":"1999","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-52","first-page":"624","volume-title":"B cells in systemic sclerosis: A possible target for therapy","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev"},{"key":"key-10.4103\/0019-5154.113930-53","first-page":"3167","volume-title":"B cell infiltration in systemic sclerosis-associated interstitial lung disease","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-54","first-page":"112","volume-title":"B-cell depletion with rituximab: A promising treatment for diffuse cutaneous systemic sclerosis","author":"Van","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key-10.4103\/0019-5154.113930-55","first-page":"2228","volume-title":"The controversial role of tumor necrosis factor \u03b1 in fibrotic diseases","author":"Distler","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-56","first-page":"289","volume-title":"Biologic therapy for systemic sclerosis: A systematic review","author":"Phumethum","year":"2011","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-57","doi-asserted-by":"crossref","unstructured":"Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis Arthritis Rheum 2009;60:578-83.","DOI":"10.1002\/art.24249"},{"key":"key-10.4103\/0019-5154.113930-58","doi-asserted-by":"crossref","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study Rheumatology 2010;49:271-80.","DOI":"10.1093\/rheumatology\/kep093"},{"key":"key-10.4103\/0019-5154.113930-59","first-page":"R54","volume-title":"B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key-10.4103\/0019-5154.113930-60","first-page":"2408","volume-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","author":"Shima","year":"2010","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-61","first-page":"686","volume-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: Presentation of two cases","author":"Stausb\u00f8l-Gr\u00f8n","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/0019-5154.113930-62","first-page":"1245","volume-title":"Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis","author":"Scherer","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-63","first-page":"1636","volume-title":"Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease","author":"Lam","year":"2007","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-64","first-page":"1433","volume-title":"An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis","author":"Denton","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-65","first-page":"173","volume-title":"Emerging targets for the treatment of Scleroderma","author":"Leask","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"key-10.4103\/0019-5154.113930-66","first-page":"51","volume-title":"Imatinib and the treatment of fibrosis: Recent trials and tribulations","author":"Gordon","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"key-10.4103\/0019-5154.113930-67","first-page":"1003","volume-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-68","first-page":"153","volume-title":"Treatment of systemic sclerosis with D-penicillamine.A new method of observing the effects of treatment","author":"Bluestone","year":"1970","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-69","first-page":"23166","volume-title":"Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway","author":"Shegogue","year":"2004","journal-title":"J Biol Chem"},{"key":"key-10.4103\/0019-5154.113930-70","first-page":"445","volume-title":"Halofuginone: A novel antifibrotic therapy","author":"Pines","year":"1998","journal-title":"Gen Pharmacol"},{"key":"key-10.4103\/0019-5154.113930-71","first-page":"1063","volume-title":"A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset","author":"Derk","year":"2008","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-72","first-page":"3821","volume-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study","author":"Su","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-73","first-page":"417","volume-title":"Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma","author":"Pines","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"key-10.4103\/0019-5154.113930-74","first-page":"98","volume-title":"Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis","author":"Vonk","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-75","first-page":"498","volume-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"key-10.4103\/0019-5154.113930-76","first-page":"150","volume-title":"Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis","author":"Papp","year":"2012","journal-title":"Clin Immunol"},{"key":"key-10.4103\/0019-5154.113930-77","first-page":"793","volume-title":"Systemic Sclerosis Study Group A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis","author":"Knobler","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.113930-78","first-page":"1689","volume-title":"The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice","author":"Blank","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-79","first-page":"1005","volume-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-80","first-page":"977","volume-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: A pilot study","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-81","first-page":"440","volume-title":"A randomized controlled study of low-dose UVA1, medium-doseUVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","author":"Kreuter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.113930-82","first-page":"400","volume-title":"Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts","author":"Delany","year":"1992","journal-title":"J Cell Biochem"},{"key":"key-10.4103\/0019-5154.113930-83","first-page":"1613","volume-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-84","first-page":"R30","volume-title":"High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy","author":"Hunzelmann","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key-10.4103\/0019-5154.113930-85","first-page":"42","volume-title":"Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails-A Consensus of Systemic Sclerosis Experts","author":"Walker","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-86","first-page":"726","volume-title":"Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis","author":"Pai","year":"1995","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-87","first-page":"304","volume-title":"Dexamethasone-cyclophosphamide pulse therapy in progressive systemic sclerosis","author":"Viswanath","year":"2010","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/0019-5154.113930-88","first-page":"91","volume-title":"Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis.A randomized placebo-controlled study","author":"Sharada","year":"1994","journal-title":"Rheumatol Int"},{"key":"key-10.4103\/0019-5154.113930-89","first-page":"355","volume-title":"Dexamethasone pulse therapy in patients of systemic sclerosis: Is it a viable proposition.A study from Kashmir?","author":"Sameem","year":"2010","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/0019-5154.113930-90","first-page":"578","volume-title":"Assessing microvascular changes in systemic sclerosis diagnosis and management","author":"Cutolo","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-91","first-page":"145","volume-title":"Calcium channel blockers for primary Raynaud\u2032s phenomenon: A meta-analysis","author":"Thompson","year":"2005","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-92","first-page":"1841","volume-title":"Calcium-channel blockers for Raynaud\u2032s phenomenon in systemic sclerosis","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-93","first-page":"CD000956","volume-title":"Prazosin for Raynaud\u2032s phenomenon in progressive systemic sclerosis","author":"Harding","year":"1998","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0019-5154.113930-94","first-page":"2646","volume-title":"Losartan therapy for Raynaud\u2032s phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-95","first-page":"199","volume-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis.A multicenter, placebo-controlled, double-blind study","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0019-5154.113930-96","first-page":"952","volume-title":"Oral iloprost in Raynaud\u2032s phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study","author":"Black","year":"1998","journal-title":"Br J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-97","first-page":"670","volume-title":"Oral iloprost treatment in patients with Raynaud\u2032s phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study","author":"Wigley","year":"1998","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-98","first-page":"1801","volume-title":"Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud\u2032s phenomenon and digital ulcers","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-99","first-page":"2980","volume-title":"Sildenafil in the treatment of Raynaud\u2032s phenomenon resistant to vasodilatory therapy","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"key-10.4103\/0019-5154.113930-100","first-page":"2420","volume-title":"Efficacy of tadalafil in secondary Raynaud\u2032s phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial","author":"Shenoy","year":"2010","journal-title":"Rheumatology"},{"key":"key-10.4103\/0019-5154.113930-101","first-page":"3985","volume-title":"Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0019-5154.113930-102","first-page":"32","volume-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-103","first-page":"76","volume-title":"Topical glyceryltrinitrate as adjunctive treatment in Raynaud\u2032s disease","author":"Franks","year":"1982","journal-title":"Lancet"},{"key":"key-10.4103\/0019-5154.113930-104","first-page":"636","volume-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud\u2032s phenomenon","author":"Teh","year":"1995","journal-title":"Br J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-105","first-page":"49","volume-title":"Failure of low molecular weight dextran infusions in scleroderma","author":"Kirk","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-106","first-page":"737","volume-title":"Renal failure associated with low-molecular-weight dextran infusion","author":"Morgan","year":"1966","journal-title":"Br Med J"},{"key":"key-10.4103\/0019-5154.113930-107","first-page":"339","volume-title":"Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin","author":"Berman","year":"1990","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-108","first-page":"1207","volume-title":"Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis","author":"De","year":"2009","journal-title":"Clin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-109","first-page":"97","volume-title":"Use of pentoxifylline in the treatment of systemic scleroderma","author":"Ne\u012dkoIe","year":"2002","journal-title":"LikSprava"},{"key":"key-10.4103\/0019-5154.113930-110","first-page":"426","volume-title":"Botulinum Toxin-A for the Treatmentof Raynaud Syndrome","author":"Smith","year":"2012","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0019-5154.113930-111","doi-asserted-by":"crossref","unstructured":"Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea\/linear scleroderma, J Am Acad Dermatol 1998;39:211-5.","DOI":"10.1016\/S0190-9622(98)70077-5"},{"key":"key-10.4103\/0019-5154.113930-112","first-page":"252","volume-title":"Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis.Does diltiazem induce its regression?","author":"Vayssairat","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-113","first-page":"267","volume-title":"Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline","author":"Robertson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-114","first-page":"15","volume-title":"Calcinosis cutis: Part II.Treatment options","author":"Reiter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.113930-115","first-page":"357","volume-title":"Disodium etidronate therapy for dystrophic cutaneous calcification","author":"Rabens","year":"1975","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0019-5154.113930-116","first-page":"114","volume-title":"Marked improvement of calcinosis in adult dermatomyositis with etidronatetherapy","author":"Mori","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"key-10.4103\/0019-5154.113930-117","first-page":"457","volume-title":"Treatment of calcinosis circumscripta and Raynaud\u2032s phenomena","author":"Meyers","year":"1976","journal-title":"Med J Aust"},{"key":"key-10.4103\/0019-5154.113930-118","first-page":"216","volume-title":"Treatment of calcinosis circumscripta with probenecid","author":"Dent","year":"1972","journal-title":"Brit Med J"},{"key":"key-10.4103\/0019-5154.113930-119","first-page":"3536","volume-title":"Calcinosis universalis complicating juvenile dermatomyositis: Resolution during probenecid therapy","author":"Eddy","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/0019-5154.113930-120","first-page":"1341","volume-title":"Low dose warfarin treatment for calcinosis in patients with systemic sclerosis","author":"Cukierman","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-121","first-page":"53","volume-title":"Subcutaneous morphea with dystrophic calcification with response to ceftriaxone treatment","author":"Reiter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.113930-122","first-page":"589","volume-title":"Large subcutaneous calcification in systemic lupus erythematosus: Treatment with oral aluminium hydroxide administration followed by surgical excision","author":"Park","year":"1999","journal-title":"J Korean Med Sci"},{"key":"key-10.4103\/0019-5154.113930-123","first-page":"1721","volume-title":"Calcinosis cutis in juvenile dermatomyositis: Remarkable response to aluminum hydroxide therapy","author":"Wang","year":"1988","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0019-5154.113930-124","first-page":"118","volume-title":"Treatment of Calcinosis Universalis with Aluminium Hydroxide","author":"Nassim","year":"1970","journal-title":"Arch Dis Child"},{"key":"key-10.4103\/0019-5154.113930-125","first-page":"585","volume-title":"Response of dystrophic calcification to intravenous immunoglobulin","author":"Schanz","year":"2008","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0019-5154.113930-126","first-page":"212","volume-title":"Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome","author":"Saddic","year":"2009","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0019-5154.113930-127","first-page":"480","volume-title":"A case of persistent subepidermal calcified nodule in an adult treated with CO2 laser","author":"Joo","year":"2004","journal-title":"J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-128","first-page":"302","volume-title":"Digital calcification in systemic sclerosis: Effective treatment with good tissue preservation using the carbon dioxide laser","author":"Bottomley","year":"1996","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-129","first-page":"424","volume-title":"Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy","author":"Sultan-Bichat","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.113930-130","first-page":"417","volume-title":"Effects of bosentan on nondigital ulcers in patients with systemic sclerosis","author":"Taniguchi","year":"2012","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0019-5154.113930-131","first-page":"317","volume-title":"Efficacy of Bosentan in treatment of refractory sclerodermic bone prominences skin ulcers","author":"Richetta","year":"2008","journal-title":"Clin Ter"},{"key":"key-10.4103\/0019-5154.113930-132","first-page":"1784","volume-title":"Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma","author":"Ferreira","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0019-5154.113930-133","first-page":"287","volume-title":"Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin","author":"Ferri","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/0019-5154.113930-134","first-page":"2929","volume-title":"Platelet gel in the treatment of severe scleroderma skin ulcers","author":"Giuggioli","year":"2012","journal-title":"Rheumatol Int"},{"key":"key-10.4103\/0019-5154.113930-135","first-page":"350","volume-title":"Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane","author":"Yoon","year":"2002","journal-title":"J Am Podiatr Med Assoc"},{"key":"key-10.4103\/0019-5154.113930-136","first-page":"26","volume-title":"The treatment of skin ulcers in systemic sclerosis: Use of granulocyte-colony stimulating factor (G-CSF) in 26 patients","author":"Giuggioli","year":"2006","journal-title":"Reumatismo"},{"key":"key-10.4103\/0019-5154.113930-137","first-page":"200","volume-title":"Treatment of scleroderma skin ulcers with a hydrocolloid membrane","author":"Milburn","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.113930-138","first-page":"747946","volume-title":"Lower extremity ulcers in systemic sclerosis: Features and response to therapy","author":"Shanmugam","year":"2010","journal-title":"Int J Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-139","first-page":"322","volume-title":"Management of leg ulcers in patients with rheumatoid arthritis or systemic sclerosis: The importance of concomitant arterial and venous disease","author":"Hafner","year":"2000","journal-title":"J Vasc Surg"},{"key":"key-10.4103\/0019-5154.113930-140","first-page":"487","volume-title":"The 585 nm flashlamp-pumped pulsed dye laser for the treatment of telangiectases in patients with scleroderma","author":"Ciatti","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.113930-141","first-page":"391","volume-title":"Cyclophosphamide treatment improves microvessel damage in systemic sclerosis","author":"Caramaschi","year":"2009","journal-title":"Clin Rheumatol"},{"key":"key-10.4103\/0019-5154.113930-142","first-page":"139020","volume-title":"Vascular Alterations and Sexual Function in Systemic Sclerosis","author":"Impens","year":"2010","journal-title":"Int J Rheumatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T06:38:32Z","timestamp":1563259112000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.e-ijd.org\/text.asp?2013\/58\/4\/255\/113930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"alternative-id":["113930"],"URL":"https:\/\/doi.org\/10.4103\/0019-5154.113930","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}